Big peptide news from Washington 👇 🏛️ What happened: On October 28, 2026, HHS (the department the FDA sits under) announced an interim policy covering six peptides: BPC-157, epitalon, KPV, MOTS-c, Semax and TB-500. HHS says it won't take enforcement action against state-licensed compounding pharmacies, federal facilities and licensed physicians that compound these peptides, as long as they meet strict conditions. Those include a patient-specific prescription, ingredients from FDA-registered manufacturers, a valid certificate of analysis, and reporting of safety and quality problems. 📌 What it is NOT: This is not FDA approval. HHS itself says the policy doesn't establish that these peptides are safe or effective. It's a temporary measure while the FDA works on its official compounding list, and HHS says it can revisit it if safety or quality problems show up. FDA scientists had recommended against adding these peptides at a July advisory meeting, and a patient-safety group has already petitioned the FDA to block the policy. 🔬 What it means for research buyers: • Nothing changes for Research Use Only products. The policy only covers licensed pharmacies and physicians, not RUO sellers. • HHS says one goal is to move people away from unregulated "research-use-only" peptides from foreign manufacturers, so expect regulators to keep watching the RUO market closely. • It follows FDA's August 2026 warning letters to online peptide sellers, which made it clear that a "Research Use Only" label doesn't protect a seller whose marketing points to human use. • Bottom line: stick with sellers that stay strictly research-focused and publish third-party COAs matched to each lot. You can check any of ours at theaminosignal.com/coa 🔎 🔗 Source (HHS policy document): https://www.hhs.gov/sites/default/files/hhs-503a-peptide-enforcement-discretion-policy-appendix-b.pdf